Get the Stockscreener App
31.89
1.02%
-0.33
After Hours:
31.89
Stoke Therapeutics Inc stock is traded at $31.89, with a volume of 450.84K.
It is down -1.02% in the last 24 hours and up +8.40% over the past month.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
See More
Previous Close:
$32.22
Open:
$32.95
24h Volume:
450.84K
Relative Volume:
0.56
Market Cap:
$1.82B
Revenue:
$199.89M
Net Income/Loss:
$52.48M
P/E Ratio:
37.52
EPS:
0.85
Net Cash Flow:
$61.15M
1W Performance:
+4.63%
1M Performance:
+8.40%
6M Performance:
+135.70%
1Y Performance:
+210.82%
1-Day Range:
$31.46
$33.28
1-Week Range:
$30.75
$33.48
52-Week Range:
$5.35
$38.69
Stoke Therapeutics Inc Stock (STOK) Company Profile
Name
Stoke Therapeutics Inc
Sector
Industry
Phone
781-430-8200
Address
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
31.89 | 1.84B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-26 | Initiated | Guggenheim | Buy |
| Jan-05-26 | Resumed | Chardan Capital Markets | Buy |
| Jul-18-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Mar-26-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Jul-25-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-01-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-26-23 | Resumed | Canaccord Genuity | Buy |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-24-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-31-22 | Initiated | Jefferies | Buy |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Nov-22-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-21 | Initiated | UBS | Neutral |
| May-10-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Dec-11-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Sep-29-20 | Initiated | Needham | Buy |
| Dec-18-19 | Initiated | Wedbush | Outperform |
| Nov-12-19 | Initiated | BTIG Research | Buy |
| Oct-25-19 | Initiated | H.C. Wainwright | Buy |
| Jul-15-19 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Credit Suisse | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
View All
Stoke Therapeutics Inc Stock (STOK) Latest News
Ideas Watch: What is the earnings history of Stoke Therapeutics IncQuarterly Trade Review & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
STOK: Four-year data show durable seizure reduction and cognitive gains, with phase 3 readout expected 2027 - TradingView
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Mo - pharmiweb.com
Stoke Therapeutics announces first patient dosed in Phase 1 study of STK-002 - marketscreener.com
Stoke Therapeutics announced that the dose-escalation phase for the first four cohorts of its research project will continue into 2026 and early 2027. - bitget.com
Stoke Therapeutics Announces First Patient Dosed In Phase 1 Study Of Stk-002 - TradingView
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) - Business Wire
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Earnings: What is the PEG ratio of Stoke Therapeutics IncJuly 2025 Movers & Fast Gain Stock Trading Tips - baoquankhu1.vn
Guggenheim Upgrades Stoke Therapeutics (NASDAQ:STOK) to "Strong-Buy" - MarketBeat
Why (STOK) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Earnings Recap: How does Stoke Therapeutics Inc score in quality rankingsShare Buyback & Target Return Focused Stock Picks - baoquankhu1.vn
Penserra Capital Management LLC Acquires New Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics stock jumps after Guggenheim initiates with Buy rating By Investing.com - Investing.com South Africa
Stoke Therapeutics stock jumps after Guggenheim initiates with Buy rating - Investing.com
Guggenheim Initiates Coverage on Stoke Therapeutics With Buy Rating, $60 Price Target - marketscreener.com
Guggenheim initiates Stoke Therapeutics stock with Buy rating on Dravet drug - Investing.com Canada
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - pharmiweb.com
Aug Action: Can Stoke Therapeutics Inc navigate macro headwindsEarnings Miss & Growth-Oriented Investment Plans - baoquankhu1.vn
Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Sentiment Watch: Should I hold or sell Stoke Therapeutics Inc nowJuly 2025 Opening Moves & Weekly Breakout Watchlists - baoquankhu1.vn
Breakouts Watch: Does FULT outperform in volatile marketsJuly 2025 Opening Moves & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Commit To Buy Stoke Therapeutics At $20, Earn 20.2% Annualized Using Options - Nasdaq
Stoke Therapeutics, Inc. (STOK) Investor Outlook: A Promising 27.53% Upside Potential In Biotech - DirectorsTalk Interviews
Stoke Therapeutics (NASDAQ:STOK) Trading 6.2% HigherHere's What Happened - MarketBeat
Stoke Therapeutics Expands with New Long-Term Waltham Headquarters - TipRanks
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA - Finviz
Stoke Therapeutics Shares Face Pressure from Strategic Expansion - AD HOC NEWS
Understanding Momentum Shifts in (STOK) - Stock Traders Daily
Should value investors consider Stoke Therapeutics Inc2025 Volatility Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Stoke Therapeutics (STOK) Stock Analysis: Unveiling Growth Potential with a 23.54% Upside - DirectorsTalk Interviews
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
Stoke Therapeutics, Inc. $STOK is Skorpios Trust's Largest Position - MarketBeat
Trial testing breakthrough Dravet drug zorevunersen now nearly full - Dravet Syndrome News
Stoke Therapeutics (STOK) price target increased by 10.42% to 36.46 - MSN
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Avoiding Lag: Real-Time Signals in (STOK) Movement - Stock Traders Daily
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity (NASDAQ:STOK) - Seeking Alpha
Stoke Therapeutics (STOK) Price Target Increased by 10.42% to 36.46 - Nasdaq
STOK: Phase III for Dravet therapy nears full enrollment, with durable efficacy and regulatory momentum - TradingView — Track All Markets
Stoke Therapeutics stock falls after delayed Phase 3 readout timeline By Investing.com - Investing.com Australia
Stoke Therapeutics (NASDAQ:STOK) Shares Gap DownHere's What Happened - MarketBeat
Stoke Therapeutics stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Canada
Stoke Therapeutics stock maintains Overweight rating at Cantor Fitzgerald - Investing.com
Phase III update Stokes hope; Dravet game-change Encoded? - BioWorld MedTech
Wedbush Raises Price Target for Stoke Therapeutics (STOK) to $36 - GuruFocus
Stoke Therapeutics Says US FDA Seeks Additional Information for Zorevunersen in Dravet Syndrome; Shares Fall - marketscreener.com
Stoke Therapeutics stock falls after delayed Phase 3 readout timeline - Investing.com
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $36.00 at Wedbush - MarketBeat
8 Analysts Have This To Say About Stoke Therapeutics - Benzinga
Stoke Therapeutics Inc Stock (STOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Stoke Therapeutics Inc Stock (STOK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Dec 08 '25 |
Sale |
32.28 |
3,978 |
128,411 |
11,831 |
| Kaye Edward M. MD | Director |
Dec 08 '25 |
Sale |
32.27 |
13,430 |
433,385 |
49,124 |
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):